Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Arista Networks Inc (ANET) Price & Performance

Adaptive Biotechnologies Corp
Arista Networks Inc

Price performance

Price movement over the last 24 hours

Key statistics

Adaptive Biotechnologies Corp vs Arista Networks Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Arista Networks Inc trades at $180.45 (market cap $209.60B). The key difference: Arista Networks Inc is far larger — about 62.9× Adaptive Biotechnologies Corp's market cap, and Arista Networks Inc is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.

ADPTANET
Market Cap
$3.33B$209.60B
Sector
HealthTechnology
52-Week High
$22.37$177.73
52-Week Low
$10.24$103.39
Enterprise Value
$3.19B$197.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Arista Networks Inc

Arista Networks (ANET) trades at $166.46, up 4.04% in the last session, with a bullish technical outlook and strong fundamental performance. The company reported revenue of $9.01B in 2025, with net income of $3.51B and a net margin of 38.32%. Recent quarters show consistent earnings beats, and analyst consensus is strongly bullish with a $192.82 price target. Technical indicators suggest the stock is near key resistance at $171, with support at $164.

ANET presents a compelling growth opportunity driven by AI networking demand and robust financials, but elevated valuation ratios (P/E 59.55) and competitive pressures pose risks. The stock's upside is supported by analyst optimism and institutional interest, though investors should monitor execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Arista Networks Inc

Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.

Read more on ANET